Trial Profile
A Dose Escalation Study to Assess the Safety and Ability of SG1002 to Overcome Circulating Deficits in Hydrogen Sulfide Found in Heart Failure Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sodium polysulthionate (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Sulfagenix
- 10 Apr 2020 Status changed from active, no longer recruiting to completed.
- 04 Nov 2014 New trial record